Tango Therapeutics, Inc. (TNGX) Reports In-Line Q2 EPS

Tango Therapeutics, Inc. (NASDAQ: TNGX) reported Q2 EPS of ($0.35), in-line with the analyst estimate of ($0.35). Revenue for the quarter came in at $3.18 million versus the consensus estimate of $6.42 million.

For earnings history and earnings-related data on Tango Therapeutics, Inc. (TNGX) click here.

You May Also Be Interested In

• Erste Group Upgrades salesforce.com (CRM) to Buy
• Erste Group Upgrades Abbvie (ABBV) to Buy
• Bernstein SocGen on Spotify (SPOT): 'A multi-layered audio opportunity supported by investment'